United States — Food and Drug Administration & Kyle Diamantas

United States — Food and Drug Administration: The FDA is the central regulator proposing the new notification requirement and completing the ultraprocessed food definition, enhancing its oversight role.

Kyle Diamantas: As acting FDA Commissioner, Diamantas is the public face of the proposal, articulating its benefits for postmarket safety.

United States — Food and Drug Administration: The FDA is the agency being led. It faces staff losses, morale issues, and policy controversies; Overton's nomination could exacerbate these challenges.

Kyle Diamantas: Diamantas has been acting FDA chief since May, providing some stability. His future role is uncertain under a new commissioner.

United States — Food and Drug Administration: The FDA led the investigation, linking the outbreak to Taylor Farms lettuce. It faced criticism for a false-positive test result and for potential influence by the United States — White House, but it continues to work on the investigation.

Kyle Diamantas: Acting FDA Commissioner Kyle Diamantas announced the false-positive test result, which complicated the investigation.

United States — Food and Drug Administration: The FDA granted approval for mFLUSIVA, marking a regulatory milestone and demonstrating its role in vaccine oversight despite internal controversies.

Kyle Diamantas: As acting FDA Commissioner, Diamantas sought to rebuild industry confidence after the controversies.

Kyle Diamantas: Kyle Diamantas is expected to take over as acting commissioner of the United States — Food and Drug Administration.

Kyle Diamantas: Kyle Diamantas, the United States — Food and Drug Administration's deputy commissioner for foods, is tasked with developing a definition for 'ultra-processed foods' and is the first non-scientist to head the United States — Food and Drug Administration in over half a century, raising concerns among critics.

Kyle Diamantas: Kyle Diamantas will serve as the acting commissioner of the United States — Food and Drug Administration following Marty Makary's resignation, suggesting a potential shift in the agency's approach to various regulatory issues.